Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31568981 | 0.74 | KDM4C (0.32) | KDM4CNPC1RAB9A | |
| SCHEMBL21752260 | 0.74 | KDM4C (0.34) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28782014 | 0.73 | SLC6A3 (0.34) | KDM4C | |
| SCHEMBL15349909 | 0.73 | F2RL3 (0.35) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5891959 | 0.72 | POLB (0.38) | PTGER4 | |
| SCHEMBL29757580 | 0.72 | CYP19A1 (0.40) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL24533841 | 0.71 | KDM4C (0.40) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29463654 | 0.71 | KDM4C (0.40) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28796340 | 0.70 | NPC1 (0.34) | KDM4CNPC1RAB9A | |
| SCHEMBL23852403 | 0.69 | F2RL1 (0.33) | KDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058457-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4263552-A1 | BTK DEGRADER | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022133184-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058457-A1 | BTK DEGRADER | BTK, LYN, SYK | KDM4C 536/4885NPC1 4528/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.